Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Drug ChannelsJoin Dr.Read full story pharminent May 12, 2026 (Last updated: May 12, 2026) Drug Channels Join Dr. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosisNext: BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial Related Stories Policy / Pricing US launches probe of German ‘underpayment’ for medicines pharminent June 19, 2026 Policy / Pricing FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ pharminent June 19, 2026 Policy / Pricing German said to be backtracking on pharma rebate changes pharminent June 16, 2026
